Amitai, Tamar
Kan-Tor, Yoav
Or, Yuval
Shoham, Zeev
Shofaro, Yoel
Richter, Dganit
Har-Vardi, Iris
Ben-Meir, Assaf
Srebnik, Naama
Buxboim, Amnon http://orcid.org/0000-0003-2412-9792
Funding for this research was provided by:
European Research Council (678977)
H2020 European Research Council (966830)
Article History
Received: 20 February 2022
Accepted: 9 September 2022
First Online: 4 October 2022
Declarations
:
: This research was approved by the Investigation Review Boards of the data-providing medical centers: Hadassah Hebrew University Medical center IRB number HMO 558- 14; Kaplan Medical Center IRB 0040–16-KMC; Soroka Medical Center IRB 0328–17-SOR; Rabin Medical Center IRB 0767–15-RMC.
: T.A., N.S., Y.O., Z.S., Y.S., D.R., and A.B. declare no financial or non-financial competing or other conflict of interest. I.H.V. and A.B.M. declare having no conflict of interest during the time of scientific collaboration and data collection that are relevant to this work. Since January 2020 A.B.M. serves as the Chief Medical Officer and since March 2020 I.H.V. serves as the Scientific Director of Fairtility LTD, which is a company that incorporates AI into different stages in fertility treatment. Y.K.T. declares no financial or non-financial competing or other conflict of interest. Since September 2021, Y.K.T. discloses being employed by IBM-Research.